KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Monika BRATOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Helena ČOUPKOVÁ, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ, Leona KOUBKOVA, Daniel DOLEZAL, Martin SAFANDA, Milos PESEK and Martin SVATON. Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, vol. 41, No 5, p. 2597-2603. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15039.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
Authors KREJCI, Daniel (203 Czech Republic), Petr OPALKA (203 Czech Republic), Jana KREJCI (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Petra ZEMANOVA (203 Czech Republic), Juraj KULTAN (203 Czech Republic), Ondrej FISCHER (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Monika BRATOVÁ (203 Czech Republic, belonging to the institution), Marketa CERNOVSKA (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Helena ČOUPKOVÁ (203 Czech Republic, belonging to the institution), Karolína HURDÁLKOVÁ (203 Czech Republic), Magda BAŘINOVÁ (203 Czech Republic), Leona KOUBKOVA (203 Czech Republic), Daniel DOLEZAL (203 Czech Republic), Martin SAFANDA (203 Czech Republic), Milos PESEK (203 Czech Republic) and Martin SVATON (203 Czech Republic).
Edition Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.435
RIV identification code RIV/00216224:14110/21:00122867
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.21873/anticanres.15039
UT WoS 000648660800009
Keywords in English NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed
Tags 14110215, 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/11/2021 12:49.
Abstract
Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.
PrintDisplayed: 23/7/2024 20:28